Skip to content

Dermata Therapeutics, Inc.

DRMA DRMAW

CIK 0001853816

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$7.54M
+38.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$8.26
+89.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$6.95M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
4.02M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings